Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SCZD17
MCID: CHR669
MIFTS: 26

Chromosome 2p16.3 Deletion Syndrome (SCZD17)

Categories: Genetic diseases, Mental diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Chromosome 2p16.3 Deletion Syndrome

About this section

MalaCards integrated aliases for Chromosome 2p16.3 Deletion Syndrome:

Name: Chromosome 2p16.3 Deletion Syndrome 56 71
Schizophrenia 17 56 73 29 6 71
Schizophrenia, Susceptibility to, 17 56 13
Schizophrenia Susceptibility Locus Chromosome 2p16-Related 73
Schizophrenia, Type 17 39
Sczd17 73

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Mental diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 56 614332
MeSH 43 D012559
UMLS 71 C3280524 C3808494
Sources

Summaries for Chromosome 2p16.3 Deletion Syndrome

About this section
UniProtKB/Swiss-Prot : 73 Schizophrenia 17: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

MalaCards based summary : Chromosome 2p16.3 Deletion Syndrome, also known as schizophrenia 17, is related to childhood-onset schizophrenia. An important gene associated with Chromosome 2p16.3 Deletion Syndrome is NRXN1 (Neurexin 1). The drugs Aspirin and Pantoprazole have been mentioned in the context of this disorder. Affiliated tissues include cortex, eye and brain.

OMIM : 56 Deletions at 2p16.3 involving exons of NRXN1 are associated with susceptibility to autism, schizophrenia (SCZD17), developmental delay, intellectual disability, and dysmorphic features. The phenotype is highly variable and shows incomplete penetrance (summary by Dabell et al., 2013). For a phenotypic description and a discussion of genetic heterogeneity of schizophrenia, see 181500. (614332)

Sources

Related Diseases for Chromosome 2p16.3 Deletion Syndrome

About this section

Diseases related to Chromosome 2p16.3 Deletion Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 childhood-onset schizophrenia 9.8

Sources

Symptoms & Phenotypes for Chromosome 2p16.3 Deletion Syndrome

About this section

Clinical features from OMIM:

614332
Sources

Drugs & Therapeutics for Chromosome 2p16.3 Deletion Syndrome

About this section

Drugs for Chromosome 2p16.3 Deletion Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 2, Phase 3 50-78-2 2244
2
Pantoprazole Approved Phase 2, Phase 3 102625-70-7 4679
3 Anti-Inflammatory Agents Phase 2, Phase 3
4 Anti-Ulcer Agents Phase 2, Phase 3
5 Fibrinolytic Agents Phase 2, Phase 3
6 Proton Pump Inhibitors Phase 2, Phase 3
7 Gastrointestinal Agents Phase 2, Phase 3
8 Antipyretics Phase 2, Phase 3
9 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
10 Platelet Aggregation Inhibitors Phase 2, Phase 3
11 Analgesics, Non-Narcotic Phase 2, Phase 3
12 Cyclooxygenase Inhibitors Phase 2, Phase 3
13 Antirheumatic Agents Phase 2, Phase 3
14 Analgesics Phase 2, Phase 3
15 Antacids Phase 2, Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Aspirin as Adjuvant Therapy in Young Psychotic Patients Recruiting NCT02685748 Phase 2, Phase 3 Aspirin;Placebo;Pantoprazole

Search NIH Clinical Center for Chromosome 2p16.3 Deletion Syndrome

Sources

Genetic Tests for Chromosome 2p16.3 Deletion Syndrome

About this section

Genetic tests related to Chromosome 2p16.3 Deletion Syndrome:

# Genetic test Affiliating Genes
1 Schizophrenia 17 29 NRXN1
Sources

Anatomical Context for Chromosome 2p16.3 Deletion Syndrome

About this section

MalaCards organs/tissues related to Chromosome 2p16.3 Deletion Syndrome:

40
Cortex, Eye, Brain, Testes, Cingulate Cortex
Sources

Publications for Chromosome 2p16.3 Deletion Syndrome

About this section

Articles related to Chromosome 2p16.3 Deletion Syndrome:

(show all 44)
# Title Authors PMID Year
1
Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. 56 6
21424692 2011
2
Investigation of NRXN1 deletions: clinical and molecular characterization. 56
23495017 2013
3
Phenotypic spectrum and genotype-phenotype correlations of NRXN1 exon deletions. 56
22617343 2012
4
Disruption of the neurexin 1 gene is associated with schizophrenia. 56
18945720 2009
5
Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. 56
18369103 2008
6
Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. 56
17989066 2008
7
Disruption of neurexin 1 associated with autism spectrum disorder. 56
18179900 2008
8
Clinical and brain structural effects of the Illness Management and Recovery program in middle-aged and older patients with schizophrenia. 61
31353759 2019
9
Comparison of eye movements in schizophrenia and autism spectrum disorder. 61
31774635 2019
10
Impaired attentional modulation of sensorimotor control and cortical excitability in schizophrenia. 61
31099820 2019
11
Quality indicators in the treatment of patients with depression, bipolar disorder or schizophrenia. Consensus study. 61
29317210 2018
12
Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T. 61
28243459 2017
13
The 40-Hz Auditory Steady-State Response in Patients With Schizophrenia: A Meta-analysis. 61
27732692 2016
14
Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia. 61
27244229 2016
15
Prefrontal gyrification in psychotic bipolar I disorder vs. schizophrenia. 61
26160154 2015
16
Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis. 61
25786193 2015
17
Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. 61
22742979 2012
18
A morphometric, immunohistochemical, and in situ hybridization study of the dorsal raphe nucleus in major depression, bipolar disorder, schizophrenia, and suicide. 61
22129767 2012
19
Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. 61
22299714 2012
20
Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia. 61
20538831 2012
21
Biochemical changes in the cingulum in patients with schizophrenia and chronic bipolar disorder. 61
18437276 2008
22
Absence and size of massa intermedia in patients with schizophrenia and bipolar disorder. 61
25385654 2008
23
Impaired recognition and expression of emotional prosody in schizophrenia: review and meta-analysis. 61
17766089 2007
24
Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. 61
17478080 2007
25
Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. 61
17485604 2007
26
Increased levels of serum soluble L-selectin in unmedicated patients with schizophrenia. 61
17049815 2007
27
PhenoChipping of psychotic disorders: a novel approach for deconstructing and quantitating psychiatric phenotypes. 61
16838358 2006
28
Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. 61
16687386 2006
29
The use of clozapine in adults with intellectual disability. 61
15312058 2004
30
Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. 61
15237077 2004
31
Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: a structured clinical study on dual and triple diagnoses. 61
15176762 2004
32
Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. 61
12968127 2003
33
Impaired visuomotor integration in acute schizophrenia. 61
12872206 2003
34
[Investigation of recent problems in an acute care psychiatric ward considering the number psychiatrists working in the ward]. 61
12078107 2002
35
Left ear (right temporal hemisphere) advantage and left temporal hemispheric dysfunction in schizophrenia. 61
11693689 2001
36
Visual information-processing impairments in deficit and nondeficit schizophrenia. 61
9137120 1997
37
Psychogenic (reactive) and hysterical psychoses: a cross-system reliability study. 61
9065675 1997
38
[Patterns of the use of electroconvulsive therapy in Barcelona]. 61
8667659 1996
39
Maintenance of training effects on the Wisconsin Card Sorting Test by patients with schizophrenia or affective disorders. 61
8267109 1994
40
Cocaine abuse among schizophrenic patients. 61
2386250 1990
41
Inpatient diagnoses during Adolf Meyer's tenure as director of the Henry Phipps Psychiatric Clinic, 1913-1940. 61
3537208 1986
42
Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients. 61
2873821 1986
43
Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. 61
6281883 1982
44
The late positive component of the evoked response in acute schizophrenics during a test of sustained attention. 61
7357059 1980
Sources

Variations for Chromosome 2p16.3 Deletion Syndrome

About this section

ClinVar genetic disease variations for Chromosome 2p16.3 Deletion Syndrome:

6 (show all 21) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NRXN1 deletion Pathogenic 560057 2:51057824-51172182 2:50830687-50945045
2 NRXN1 NM_001330078.2(NRXN1):c.4291_4294dup (p.Gly1432fs)duplication risk factor 30095 rs1558507406 2:50149311-50149312 2:49922173-49922174
3 NRXN1 NM_001330078.2(NRXN1):c.2605C>A (p.Leu869Met)SNV Conflicting interpretations of pathogenicity 93592 rs201818223 2:50724745-50724745 2:50497607-50497607
4 NRXN1 NM_001330078.2(NRXN1):c.322C>T (p.Pro108Ser)SNV Conflicting interpretations of pathogenicity 93599 rs199784029 2:51255090-51255090 2:51027952-51027952
5 NRXN1 NM_001330078.2(NRXN1):c.600C>T (p.Gly200=)SNV Conflicting interpretations of pathogenicity 503668 rs201481698 2:51254812-51254812 2:51027674-51027674
6 NRXN1 NM_001330078.2(NRXN1):c.4011G>C (p.Glu1337Asp)SNV Conflicting interpretations of pathogenicity 206282 rs200935246 2:50280526-50280526 2:50053388-50053388
7 NRXN1 NM_001330078.2(NRXN1):c.2459G>A (p.Ser820Asn)SNV Conflicting interpretations of pathogenicity 206242 rs80293130 2:50733671-50733671 2:50506533-50506533
8 NRXN1 NM_001330078.2(NRXN1):c.2190G>T (p.Gln730His)SNV Uncertain significance 206232 rs199978276 2:50758522-50758522 2:50531384-50531384
9 NRXN1 NM_001330078.2(NRXN1):c.1978G>A (p.Ala660Thr)SNV Uncertain significance 206276 rs199939303 2:50765556-50765556 2:50538418-50538418
10 NRXN1 NM_001330078.2(NRXN1):c.302C>G (p.Ala101Gly)SNV Uncertain significance 206227 rs200184823 2:51255110-51255110 2:51027972-51027972
11 NRXN1 NM_001330078.2(NRXN1):c.262C>G (p.Arg88Gly)SNV Uncertain significance 206235 rs748684256 2:51255150-51255150 2:51028012-51028012
12 NRXN1 NM_001330078.2(NRXN1):c.3542A>G (p.His1181Arg)SNV Uncertain significance 206267 rs200915287 2:50463931-50463931 2:50236793-50236793
13 NRXN1 NM_001330078.2(NRXN1):c.3407C>T (p.Thr1136Met)SNV Uncertain significance 206265 rs138261348 2:50464066-50464066 2:50236928-50236928
14 NRXN1 NM_001330078.2(NRXN1):c.3365-109939C>TSNV Uncertain significance 206264 rs766942777 2:50574047-50574047 2:50346909-50346909
15 NRXN1 NM_001330078.2(NRXN1):c.2533C>T (p.His845Tyr)SNV Uncertain significance 206245 rs199784139 2:50724817-50724817 2:50497679-50497679
16 NRXN1 NM_001330078.2(NRXN1):c.665_673dup (p.Glu222_Glu224dup)duplication Uncertain significance 539879 rs774230140 2:51254738-51254739 2:51027600-51027601
17 NRXN1 NM_001330078.2(NRXN1):c.1784G>A (p.Arg595His)SNV Uncertain significance 423467 rs761279630 2:50765750-50765750 2:50538612-50538612
18 NRXN1 NM_001330078.2(NRXN1):c.1700T>G (p.Leu567Trp)SNV Uncertain significance 93587 rs372311299 2:50779784-50779784 2:50552646-50552646
19 NRXN1 NM_001330078.2(NRXN1):c.569A>G (p.Asn190Ser)SNV Uncertain significance 167390 rs200792504 2:51254843-51254843 2:51027705-51027705
20 NRXN1 NM_001330078.2(NRXN1):c.270G>T (p.Gln90His)SNV Uncertain significance 195130 rs199960045 2:51255142-51255142 2:51028004-51028004
21 NRXN1 NM_001330078.2(NRXN1):c.3365-109902C>TSNV Uncertain significance 625988 rs113067443 2:50574010-50574010 2:50346872-50346872
Sources

Expression for Chromosome 2p16.3 Deletion Syndrome

About this section
Search GEO for disease gene expression data for Chromosome 2p16.3 Deletion Syndrome.
Sources

Pathways for Chromosome 2p16.3 Deletion Syndrome

About this section
Sources

GO Terms for Chromosome 2p16.3 Deletion Syndrome

About this section
Sources

Sources for Chromosome 2p16.3 Deletion Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....